Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

Louise Linde* (Corresponding Author), Lykke Midtbøll Ørnbjerg, Stylianos Georgiadis, Simon H. Rasmussen, Ulf Lindström, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K Wallman, Bjorn Gudbjornsson, Thorvardur Jon Love, Dan Nordström, Timo Yli-Kerttula, Lucie Nekvindova, Jiří Vencovský, Florenzo Iannone, Alberto Cauli, Anne Gitte Loft, Bente Glintborg, Karin LaasZiga Rotar, Matija Tomšič, Gary Macfarlane, Burkhard Möller, Marleen G.H. Van de Sande, Catalin Codreanu, Michael J Nissen, Merih Birlik, Sukran Erten, Maria J Santos, Elsa Vieira-Sousa, Merete Lund Hetland, Mikkel Østergaard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries.
Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors.
In the pooled cohort (n=13,369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n=6,954, n=5,275 and n=13,369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs. women: 1.85 (1.54-2.23); CRP >10 vs. ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99).
Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.
Original languageEnglish
Early online date14 Jun 2023
Publication statusE-pub ahead of print - 14 Jun 2023

Bibliographical note

This work was supported by Novartis Pharma AG.

The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript.

Data Availability Statement

The data in this article was collected in the individual registries and made available for secondary use through the EuroSpA Research Collaboration Network [] Relevant patient level data may be made available on reasonable request to the corresponding author, but will require approval from all contributing registries.


  • psoriatic arthritis
  • first TNF-inhibitor
  • predictors
  • DAPSA28
  • drug retention
  • real-world evidence


Dive into the research topics of 'Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries'. Together they form a unique fingerprint.

Cite this